GABRE — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15406	0.61	20/20
Fipronil (SCHEMBL15088)	0.59	20/20
SCHEMBL41972	0.59	20/20
Fipronil (SCHEMBL44222)	0.59	20/20
Ethiprole (SCHEMBL27048)	0.56	20/20
SCHEMBL25897	0.51	20/20
SCHEMBL33214	0.52	19/20
SCHEMBL26584	0.51	19/20
SCHEMBL9107	0.56	12/20
SCHEMBL8532	1.00	11/20
SCHEMBL9035	0.56	10/20
SCHEMBL8632	0.54	10/20
SCHEMBL8670	0.57	9/20
SCHEMBL8856	0.53	9/20
SCHEMBL9273	0.53	9/20
SCHEMBL8931	0.51	9/20
SCHEMBL8932	0.51	9/20
SCHEMBL9163	0.58	8/20
SCHEMBL8941	0.54	8/20
SCHEMBL8047	0.56	7/20

Clinical trials — most relevant to GABRE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Levetiracetam on Alcohol Dependent Subjects	PHASE4	COMPLETED
Computational Assessment of GABA Receptor Modulation in PTSD	PHASE4	RECRUITING
Multimodal Versus Opioid aNalgesia in carDiAc Surgery	PHASE4	COMPLETED
Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia	PHASE2/PHASE3	COMPLETED
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia	PHASE2	COMPLETED
Diazepam Trial in GAD65 Associated Epilepsy	PHASE1/PHASE2	WITHDRAWN
Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia	PHASE1/PHASE2	COMPLETED
Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome	PHASE2	RECRUITING
Dopaminergic Therapy for Frontotemporal Dementia Patients	PHASE2	COMPLETED
Vigabatrin for Treatment of Cocaine Dependence	PHASE2	COMPLETED
Effects of Baclofen on Presynaptic Inhibition in Humans	PHASE2	WITHDRAWN
Physiologic Effects of Topiramate on Cognition	PHASE1	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
MEG Study of Acute STX209 Effects in ASD	EARLY_PHASE1	COMPLETED
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression	EARLY_PHASE1	RECRUITING
Creatine and Motor Skill Acquisition	EARLY_PHASE1	UNKNOWN
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy	nan	UNKNOWN
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
Cenobamate Efficacy in Individuals With Autoimmune Epilepsy	nan	ENROLLING_BY_INVITATION
Exploring the Role of the Prefrontal Cortex in Decision-Making	nan	RECRUITING
Brain Function in Focal Dystonia	nan	COMPLETED
Transcranial Direct Current Stimulation in Autism Spectrum Disorder	nan	COMPLETED
Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.	nan	RECRUITING
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
GABA Biomarkers in Dravet Syndrome	nan	RECRUITING
Menopause Effects on Cortico-reticular Functioning	nan	RECRUITING
Influence of Brain Oscillation-Dependent TMS on Motor Function	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GABRE binder may also engage these)

Protein	Name	Similarity
Q9ES14	—	0.987	Q9ES14 →
P09484	—	0.976	P09484 →
Q9ERK7	—	0.975	Q9ERK7 →
P25110	—	0.975	P25110 →
P05376	—	0.975	P05376 →
P49580	—	0.974	P49580 →
P49579	—	0.974	P49579 →
CHRND	Acetylcholine receptor subunit delta	0.974	landscape →
P12392	—	0.974	P12392 →
Q28738	—	0.973	Q28738 →
P02717	—	0.972	P02717 →
P18506	—	0.972	P18506 →
P37090	—	0.972	P37090 →
P02716	—	0.971	P02716 →
P09628	—	0.971	P09628 →
P04759	—	0.971	P04759 →
GABRD	Gamma-aminobutyric acid receptor subunit delta	0.969	landscape →
P09480	—	0.969	P09480 →
Q68RJ7	—	0.969	Q68RJ7 →
Q8R493	—	0.968	Q8R493 →
SCNN1G	Epithelial sodium channel subunit gamma	0.967	landscape →
P12390	—	0.967	P12390 →
P04755	—	0.967	P04755 →
Q9WU39	—	0.966	Q9WU39 →
CHRNB4	Neuronal acetylcholine receptor subunit beta-	0.966	landscape →
P26153	—	0.966	P26153 →
P12389	—	0.966	P12389 →
CHRNB2	Neuronal acetylcholine receptor subunit beta-2	0.966	landscape →
CHRNA4	Neuronal acetylcholine receptor subunit alpha-4	0.965	landscape →
Q5IS52	—	0.965	Q5IS52 →